论文部分内容阅读
目的:分析冠心病患者血脂异常运用普伐他汀治疗的临床疗效。方法:选取2015年1月至2015年10月高州市中医院收治的冠心病患者118例为研究对象,按照治疗方式的不同分成两组。对照组实施常规治疗,观察组患者在此基础上采用普伐他汀。两组患者跟踪随访1年,比较血脂变化情况以及治疗效果。结果:观察组患者的血脂调节情况比对照组患者的调节速度明显快,治疗后6个月,观察组患者血脂达标情况明显优于对照组,差异具有统计学意义(P<0.05)。观察组总有效率达到98.33%(59/60),对照组达到86.21%(50/58),组间比较,差异具有统计学意义(P<0.05)。接受治疗过程中,观察组患者不良反应发生率为11.67%,对照组为3.45%,两组比较,差异具有统计学意义(P<0.05)。结论:冠心病患者血脂异常运用普伐他汀治疗的临床疗效显著,患者血脂情况改善较好,治疗效果得到显著提高。但是临床应用中,普伐他汀可能会导致肝功能损害,有肝病史或饮酒史的病人应慎用,治疗期间要注意查肝功能。
Objective: To analyze the clinical effect of pravastatin on dyslipidemia in patients with coronary heart disease. Methods: From January 2015 to October 2015, 118 cases of coronary heart disease admitted to Gaozhou Hospital of Traditional Chinese Medicine were selected as the research object and divided into two groups according to different treatment methods. The control group received routine treatment, and the observation group patients received pravastatin on this basis. Two groups of patients were followed up for 1 year, comparing changes in blood lipids and treatment. Results: In the observation group, the regulation of blood lipid was significantly faster than that of the control group. At 6 months after treatment, the observation group achieved significantly better blood lipid compliance than the control group (P <0.05). The total effective rate was 98.33% (59/60) in the observation group and 86.21% (50/58) in the control group. The differences between the two groups were statistically significant (P <0.05). During the course of treatment, the incidence of adverse reactions in the observation group was 11.67% and in the control group was 3.45%. There was significant difference between the two groups (P <0.05). Conclusion: The clinical efficacy of pravastatin in patients with coronary heart disease was significantly lower than that in patients with dyslipidemia. The improvement of blood lipids in patients with coronary heart disease was better and the treatment effect was significantly improved. However, in clinical practice, pravastatin may cause liver damage, patients with a history of liver disease or alcohol consumption should be cautious, check the liver function during treatment.